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ABSTRACT
Purpose: The purpose of our study was to determine the
maximum-tolerated dose, dose-limiting toxicity, safety pro-
file, and pharmacokinetics of the polyamine synthesis inhib-
itor SAM486A given in combination with 5-fluorouracil/
leucovorin (5-FU/LV) in cancer patients.
Experimental Design: Patients with advanced colorectal
cancer were treated with 5-FU [bolus (400 mg/m2) followed
by a 22-h infusion (600 mg/m2)] and LV (200 mg/m2) and
escalating doses of SAM486A, 1–3-h infusion daily for 3
days. Plasma sampling was performed to characterize the
pharmacokinetics and pharmacodynamics of the combina-
tion
Results: Twenty-seven patients with metastatic colorec-
tal cancer and 1 with pseudomyxoma peritonei were treated.
Twenty-six patients received SAM486A in the combination
at doses ranging from 25 to 150 mg/m2/day. Dose-limiting
toxicity consisting of fatigue grade 3 was seen at 150 mg/m2/
day. Other adverse events included neutropenia, hand and
foot syndrome, nausea, vomiting, diarrhea, and constipa-
tion. Fifteen of 26 patients evaluable for best response ac-
cording to the Southwest Oncology Group criteria achieved
a partial response [8 (30%) of 26] or stable disease [9 (35%)
of 26]. SAM486A did not influence the pharmacokinetics of
5-FU, and SAM486A clearance was similar to that when
used as a single agent.
Conclusions: The novel molecular agent SAM486A is
tolerable and safe in combination with a standard 5-FU
regimen in patients with advanced colorectal cancer. The
dose of SAM486A recommended for additional studies with
this combination is 125 mg/m2/day. A disease-directed eval-
uation of SAM486A using this regimen is warranted.
INTRODUCTION
The polyamines spermidine and spermine play an essential
role in the growth of cells, although their specific mechanism of
action remains to be elucidated. Tumor cells have an altered
polyamine homeostasis resulting in elevated polyamine pools.
The key process in the biosynthesis of polyamines is the con-
version from putrescine to spermidine and spermine for which
S-adenosyl methionine decarboxylase (SAMDC) activity is the
rate-limiting step (1). The activity of this enzyme can specifi-
cally be inhibited by novel agents such as SAM486A (2). In in
vitro studies SAM486A depleted spermine and spermidine
pools, whereas putrescine pools increased (2). SAM486A
showed growth-inhibitory effects on human melanoma-, breast
cancer-, and bladder cancer cell lines (3–6) with a similar
spectrum of in vivo activity especially in melanoma and prostate
cancer xenografts with almost complete inhibition of growth
over the treatment period (3, 7). Recently, two Phase I studies
with SAM486A in patients with various advanced solid tumors
using a dosing schedule of either 120-h infusions every 4 weeks
or 4 weekly infusions followed by 2 weeks off therapy demon-
strated that the primary dose-limiting toxicity (DLT) was mye-
losuppression (8, 9). Nonhematological side effects included
gastrointestinal toxicity (nausea/vomiting), fatigue (mild and
short lasting), facial paresthesias and flushing, and alopecia. No
complete or partial responses were recorded.
For some time, 5-fluorouracil (5-FU) in combination with
leucovorin (LV) has been the standard palliative chemotherapy
for metastatic colorectal cancer (10). Recently, newer drugs
such as oxaliplatin and irinotecan have contributed to improved
survival and are being incorporated into novel schedules (11–
14). In addition to these chemotherapeutic agents, cellular tar-
gets have been the basis for novel approaches of which S-
adenosyl-methionine decarboxylase is one. Adenocarcinoma of
the colon contains high levels of S-adenosyl methionine decar-
boxylase (15), and consequent on positive xenograft data,4 a
combination of 5-FU/LV with SAM486A was considered to be
a rational option. We performed a Phase I and pharmacological
study with the aim of developing a once-every-2-weeks-
treatment regimen based on SAM486A combined with a
5-FU/LV regimen (the de Gramont regimen), an effective reg-
imen with less toxicity than the more common once-every-4-
weeks regimen (16).
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PATIENTS AND METHODS
Eligibility. Patients with a histologically confirmed di-
agnosis of locally advanced progressive or metastatic colorectal
cancer, or patients with solid tumors of any kind for which no
standard therapies exist with greater potential benefit than
5-FU/LV and SAM486A, were candidates for this study. Addi-
tional eligibility criteria were: age 18 years; Karnofsky per-
formance status 60%; life expectancy of at least 3 months; off
previous anticancer therapy for at least 4 weeks; adequate bone
marrow function (absolute neutrophil count 2.0  109/liter;
platelet count 100  109/liter), normal hepatic function (bil-
irubin level normal; other liver function tests 2.5 times upper
limit of normal or 5 times upper limit of normal in case of the
presence of liver metastases) and normal renal function (calcu-
lated creatinine clearance 60 ml/min); no severe cardiac in-
sufficiency (New York Heart Association class III and IV); and
a baseline left ventricular ejection fraction within normal limits,
measured by multiple gated acquisition scan or cardiac ultra-
sound. Written informed consent was obtained from all patients,
and the Institutional Ethics Committees approved the study.
Because the SAM486A dose-finding study was combined with
a standard treatment for locally advanced progressive or meta-
static colorectal cancer, there were no concerns that most of the
patients in this Phase I study (20 of 26) had not received
previous standard chemotherapy. For the patients with locally
advanced progressive disease, there were no local treatment
options like surgery.
Pretreatment and Follow-Up Studies. Pretreatment
evaluation consisted of recording the medical history, physical
examination, laboratory studies, electrocardiography, and as-
sessment of the left ventricular ejection fraction. Computer
tomographic scans were performed for tumor measurements.
General laboratory studies included a complete blood cell count,
differential WBC, electrolytes (sodium, potassium, chloride,
calcium, and inorganic phosphate), creatinine, urea, alkaline
phosphatase, aspartate aminotransferase, alanine aminotrans-
ferase, lactate dehydrogenase, bilirubin, total protein, albumin,
glucose, uric acid, and urinalysis. History, physical examination,
and toxicity scoring (according to the National Cancer Institute/
NIH Common Toxicity Criteria) were repeated weekly. Com-
plete blood cell counts, including differential WBC, were re-
peated weekly and, in case of abnormalities, twice weekly; the
other laboratory studies were repeated every other week. Elec-
trocardiography was repeated frequently during the first three
courses and thereafter if clinically significant. A final assess-
ment was to be made after patients went off study. Formal tumor
measurements were performed at 6-week intervals until docu-
mentation of progressive disease. Standard WHO response cri-
teria were used.
Drug Administration. The “de Gramont” regimen in-
cludes 200 mg/m2 LV as a 2-h infusion followed by an i.v. bolus
5-FU)400 mg/m2) and a 22-h infusion of 600 mg/m2 5-FU on
days 1 and 2, administered every 2 weeks for a maximum of 12
cycles (16). All of the patients received premedication with
5HT3 antagonists. From cycle 2 onwards, SAM486A was ad-
ministered as a 1–3-h infusion on days 1–3, to be given on days
1 and 2 with the i.v. bolus 5-FU and, on day 3, 3 h before the end
of the 22-h infusion of 5-FU. SAM486A (Novartis Pharma AG,
Basel, Switzerland) was supplied as a freeze-dried, light yellow
powder for reconstitution in a 5% dextrose solution. Besides the
active ingredient, the formulation contained lactic acid, manni-
tol, and sodium chloride. The reconstituted solution was admin-
istered using a syringe infusion pump. The infusion time of 1–3
h was based on Phase I data demonstrating facial flushing,
paresthesias, and somnolence with shorter infusion duration (9).
Furthermore, Phase I data suggested a SAM486A dosing fre-
quency of three infusions semimonthly, and a starting daily dose
of 25 mg/m2 SAM486A was selected based on tolerability in
Phase I trials. The starting dose was less than one-third of the
single-agent maximum tolerated dose (MTD; Refs. 8, 9). For
dose escalation, a modified continual reassessment method was
used (17). In each cohort, at least three patients were treated and
were evaluated for DLT after receiving one cycle of the com-
bination treatment. On the basis of this updated information, the
dose level for the next cohort was determined, and a maximum
of 100% increase in dosage was allowed. The MTD was defined
as the dose that was recommended by the modified-continual-
reassessment method after a minimum of 15 patients had been
treated in the study and at which at least 6 patients had been
enrolled. In addition, the MTD was defined as the highest daily
dose of SAM486A given for 3 days in combination with a
fixed-dose every 2 weeks of 5-FU and LV at which no more
than 25% of the patients treated at that dose level experienced
DLT. DLT was defined as grade 4 neutropenia lasting more than
5 days, neutropenic fever, any grade 4 thrombocytopenia, and
any nonhematological toxicity of more than grade 2 except
alopecia, inadequately treated nausea/vomiting, and/or diarrhea.
Sample Collection and Processing. Blood samples were
taken in all of the patients during cycles 1 and 2. Blood volumes
of 5–10 ml were drawn from a peripheral venous access device
inserted in the arm contralateral to the drug infusion. In patients
selected to receive the 125-mg/m2/day dose of SAM486, sam-
ples for 5-FU analysis were collected before the bolus infusion
and at 5, 10, 20, and 30 min; 1, 2, 7, 22 (just before end of
infusion), 22.25 (15 min after end of infusion) h, and 22.5 h (30
min after end of infusion) after the bolus. For determination of
SAM486A concentrations, blood samples were collected imme-
diately before the third SAM486A infusion, and just before (10
min) the end of the infusion, and at 1, 3, 6, 8, 20–24, and 44–48
h after the end of SAM486A infusion. All of the blood samples
were collected in Vacutainer tubes containing sodium heparin
(Becton Dickinson, Meylan, France) and were inverted several
times and immediately placed on ice. Within 15 min of blood
collection, samples were centrifuged at room temperature for 15
min at 2500  g to yield plasma, which was stored frozen at
20°C in polypropylene vials (Eppendorf, Hamburg, Germany)
until analysis.
Drug Analysis. Concentrations of 5-FU in plasma were
determined using a validated analytical procedure based on
high-performance liquid chromatography (18). Sample pretreat-
ment involved a solvent extraction of 1-ml aliquots with five
volumes of ethyl acetate (extraction recovery, 90%). Chro-
matographic separations of the analyte, the internal standard
(5-chlorouracil), and matrix constituents were achieved on a
5-m Inertsil ODS-3 column (250  4.6 mm inner diameter)
and isocratic elution with acidified water (pH 2.0). The column
effluent was monitored at a wavelength of 266 nm. The lower
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limit of quantitation was 0.20 M (26 ng/ml). Concentrations
of SAM486A in plasma were also determined using a liquid
chromatographic assay. One-ml sample aliquots, containing the
structural analog CGP 51467 as an internal standard, were
analyzed. The analytes were separated from interfering plasma
proteins by on-line dialysis across a Cuprophan membrane
(molecular weight limit, Mr 15,000) using a Gilson ASTED XL
on-line deproteinization autosampler fitted with a flat-bed dia-
lyzer. The dialysate was loaded onto a trace-enrichment car-
tridge, and the concentrated analytes were eluted from the
trace-enrichment cartridge into the analytical column with high-
performance liquid chromatography mobile phase. Chromato-
graphic separation of the compounds was achieved using a
3.5-m Zorbax SB-C8 column (150  4.6 mm inner diameter)
and eluted with a 0.01 M solution of octanesulfonate in a mixture
of 0.01 M potassium phosphate buffer (pH 2.5) and acetonitrile
(78:22), at a flow rate of 1 ml/min. The analytes were detected
with a UV detector monitoring at a wavelength of 230 nm. The
lower limit of quantitation was based on the accuracy and
precision of sample determinations. It was set at the lowest
concentration quality-control sample for which accuracy was in
the range 80–120% and precision was 20% coefficient of
variation. During the course of the study, the dynamic range of
the method was adjusted to the concentrations expected in the
study samples. For different assay runs, therefore, the lower
limit of quantitation varied from 5 to 50 ng/ml.
Calibration curves (y  mx  b), were generated from the
plots of the peak area ratios (y) of 5-FU and SAM486A to the
internal standard versus the concentrations (x) of the calibration
samples, using weighted (1/y) linear least-squares regression.
Concentrations in quality control and study samples were cal-
culated using a validated macro from the resulting peak area
ratios and interpolation from the regression equations of the
respective calibration curves.
PK Analysis. Pharmacokinetic (PK) analysis was per-
formed by noncompartmental analysis using WinNonlin Profes-
sional (version 1.5) software (Scientific Consulting, Inc). The
AUC0-t (area under the plasma concentration-time curve to the time
of last measurable concentration) was calculated by the linear
trapezoidal rule, and the systemic clearance was estimated as the
total drug dose administered (in mg/m2) divided by AUC0-t. AUC0-t
was used as an approximation of AUC0- in the calculation of
clearance because the rate constant of the terminal disposition
phase could not be adequately determined in many cases. However,
after the end of infusion, 5-FU levels decline to low levels very
rapidly, and, therefore, the contribution to AUC due to extrapolat-
ing from the last time point to infinity should be very small
compared with AUC0-. The Cmax (peak plasma concentration)
was put on par with concentrations observed at the end of infusion,
and the T1/2 (half-life) was determined from the rate constant of the
terminal disposition phase by a linear regression analysis. PK
characteristics of 5-FU after concomitant treatment with
SAM486A were compared with that after 5-FU treatment without
SAM486A by calculation of the ratio of clearance values. Scatter-
plots of AUC0-t versus dose, and of Cmax versus dose, were created
to evaluate the effect of dose on the systemic exposure and peak
levels. The dose proportionality of relationships between AUC or
Cmax and the administered dose of SAM486A was determined by
a least-squares linear regression analysis.
Statistical Considerations. Parameters of all of the com-
pounds are reported as mean values	 SD. The difference in PK
parameters between the 5-FU administration days and between
patient cohorts was evaluated statistically using a two-sided
parametric matched-pairs Student’s t test (after testing for nor-
mality). Ps (two-sided) of less than 0.05 were considered sta-
tistically significant. All of the calculations were done on the
Number Cruncher Statistical Systems v5. software package
(J. L. Hintze, East Kaysville, UT, 1992).
Table 1 Patient characteristics
Characteristic No. of patients
Patients included 28
Sex
Male 14
Female 14
Age, years
Median 57
Range 22–79
Performance score (ECOG)
0 8
1 20
Primary site of disease
Colon 19
Rectum 8
Pseudomyxoma peritonei 1
Prior therapy
Surgery 27
Radiotherapy 7
Chemotherapy 6
a ECOG, Eastern Cooperative Oncology Group.
Table 2 Treatment summary
Cohort
Dose SAM486A
(mg/m2/day)
No. of
patients
Median no.
of cycles
1 25 3 12
2 50 3 12
3 100 3 12
4 150 3 3
5 125 16 6
Total 28 12
Table 3 Reasons for preliminary withdrawal
Dose level Patient number/after cycle Reason
25 mg/m2 3/3 PDa
50 mg/m2 1/9 PD
150 mg/m2 2/2 Unrelated renal dysfunction
125 mg/m2 1/3 Withdrew consent
3/3 Adverse event
4/3 Adverse event
5/3 PD
6/11 PD
8/6 PD
9/3 Adverse event
UK1/7 Adverse event
UK3/6 Adverse event
UK4/4 PD
UK5/3 PD
a PD, progressive disease, UK, United Kingdom.
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RESULTS
Twenty-eight patients were entered into this study. Patient
characteristics are listed in Table 1; all of the patients were
eligible. Only six patients received prior chemotherapy in an
adjuvant setting (six cycles) at least more than 6 months before
the detection of the metastatic disease. Two patients were not
considered evaluable for toxicity, response, and PK analysis.
They did not receive combination treatment with SAM486A
because of cerebral infarction and rapid progression of skin
metastases, respectively, after treatment with 5-FU and LV in
cycle 1. An additional patient received only limited treatment.
He developed renal impairment after cycle 2, secondary to
renovascular disease and also grade 3 fatigue and did not receive
additional SAM486A. He was, however, included in the toxicity
and response evaluation. Therefore, 26 patients were included in
the analysis of response.
Toxicity and Compliance. A total of 214 cycles 5-FU/
LV, including 188 cycles of combined 5-FU/LV and
SAM486A, were given. Table 2 lists the number of patients and
the median number of cycles at each dose level. Twelve of the
26 patients received all 12 cycles. Seven patients went off study
because of progressive disease (Table 3). The treatment was
stopped in five patients because of adverse events. One patient
withdrew his consent after cycle 3, and one patient developed
unrelated abnormal renal function. The hematological and main
nonhematological adverse events are listed in Table 4 and 5,
respectively. DLT at the dose level of 150 mg/m2 consisted of
fatigue grade 3 in two of three patients resulting in a decrease in
WHO performance score from 1 to 3 after cycle 2, i.e., after the
addition of SAM486A to the 5-FU/LV regimen. After cycle one
with only 5-FU/LV, there was no decline in condition seen in
either patient. One of these two patients continued to be treated
with SAM486A at a reduced dose of 100 mg/m2 for a total of 12
cycles and subsequently experienced only grade 1 fatigue. The
other patient went off study because of an unrelated renal
function disorder. A third patient in the 150-mg/m2 group ex-
perienced grade 1 fatigue and, although she complained of
dizziness grade 2 and facial paresthesias grade 2 during the
infusions with SAM486A, she received all 12 cycles. At the
lower dose levels, drug-related fatigue was reported by 19
patients after cycle 2 or later, but it never exceeded grade 2
except in 1 patient at the dose level of 25 mg/m2 and 3 patients
at 125 mg/m2, leading to a dose reduction of SAM486A to 100
mg/m2 after four cycles and the termination of treatment after
cycle 6 in one of these 3 patients. Eight patients at the other dose
levels reported grade 1 dizziness and facial paresthesias. In
seven (27%) patients, somnolence grade 1 was observed. Skin
toxicity, particularly hand-foot syndrome, was seen in 15 pa-
tients (58%); however, in only one patient at the dose level of
125 mg/m2 did hand and foot syndrome toxicity exceed grade 2
resulting in a dose reduction of 5-FU/LV and cotreatment with
pyridoxine (19). Only one patient at the dose level of 125 mg/m2
did have one episode of neutropenic sepsis. As in the Phase I
single-agent studies, the periods of neutropenia were mostly
short-lived. However, in eight patients, one or two times during
the course, a delay of 1–2 weeks was necessary because of
persistent neutropenia. This was independent of the dose
SAM486A and most likely caused by the treatment with 5-FU/
LV. No cardiac toxicity was observed. Pronounced or total
alopecia (grade 2) was seen in 12 patients (46%).
Table 5 Incidence rate per patient of all treatment nonhematological adverse events (severity  grade 2)
Adverse event
Dose level SAM486A (mg/m2)
25 (n  3) 50 (n  3) 100 (n  3) 125 (n  14) 150 (n  3)
Nausea 0 1 2 9 3
Vomiting 1 0 1 3 0
Constipation 0 0 1 0 0
Diarrhea 0 1 0 8 0
Stomatitis/mucosal inflammation 0 1 1 8 2
Fatigue 2 1 2 8 2
Hand-foot syndrome 0 1 1 4 2
Dizziness 0 0 0 0 2
Somnolence 0 0 0 1 0
Paresthesia 0 0 0 0 1
Flushing 0 0 0 2 0
Neutropenic sepsis 0 0 0 1 0
Table 4 Incidence rate per patient of all treatment-related neutropenia by severity grade
Maximum
severity grade
Dose level SAM486A (mg/m2)
25 (n  3) 50 (n  3) 100 (n  3) 125 (n  14) 150 (n  3)
1 0 0 0 0 0
2 0 0 0 0 0
3 0 1 2 0 1
(33.3%) (66.7%) (33.3%)
4 0 0 1 3 1
(33.3%) (21.4%) (33.3%)
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Best tumor response was evaluated according to the South-
west Oncology Group method (20). Of 26 evaluable patients, of
whom 25 had metastatic colorectal cancer, 8 (30%) achieved a
partial response (2 of them received earlier adjuvant chemother-
apy) and 9 (35%), stable disease.
Pharmacokinetics. Eight patients receiving the 125-mg/
m2/day (MTD) dose of SAM486A had sufficient data for PK
analysis. After administration of the bolus injection and constant
rate infusion, 5-FU levels rose and then rapidly declined over
2 h to a steady state determined by infused 5-FU (500–750
ng/ml). The level of 5-FU again rapidly declined after the
second 22-h infusion was stopped. This concentration-time pro-
file is shown in Fig. 1. The 5-FU PK-curves with and without
SAM486A are similar, suggesting that the pharmacokinetics of
5-FU are unchanged by SAM486A. AUC0-t and clearance of
5-FU after both courses were calculated for the eight patients
and listed in Table 6. The geometric mean of the clearance ratios
was 0.94 supporting the hypothesis that there is no PK interac-
tion between 5-FU and SAM486A. The geometric mean 5-FU
clearance for both treatments combined in this study was 63.2
(range, 32.6–106.4) liters/h/m2, similar to that reported previ-
ously (21).
During infusion of SAM486A, the level of SAM486A rose
to a mean of 1640 ng/ml for the 125 mg/m2/day dose. The
decline of plasma concentrations immediately after the end of
infusion is shown in Fig. 2, which presents a semilogarithmic
plot of the mean SAM486A concentrations at each time point
for the five-dose cohorts (25, 50, 100, 125, and 150 mg/m2/day).
These data indicate that mean concentrations of SAM486A
increase with an increase in the dose administered. A plot of the
mean SAM486A concentration at each time point for 11 patients
in the 125-mg/m2/day (MTD) dose cohort is shown in Fig. 3,
and the relationships between AUC0-t and drug dose is shown in
Fig. 4. The AUC0-t was proportional to the dose of SAM486,
and a linear regression analysis yielded r2 values of 0.8 for this
relationship. In patients receiving the 125-mg/m2/day dose,
mean values of the PK parameters were as follows: AUC0-t,
15,400 ngh/ml (coefficient of variation, 18%; number of pa-
tients, 11); AUC0-, 27,400 ngh/ml (46%; n  9); Cmax, 1,640
ng/ml (37%; n  11); and T1/2, 45 h (63%; n  9). The values
of T1/2 and AUC0- for two of the patients were not included in
the mean, because of the uncertainty of estimating T1/2 [the
coefficient of determination (r2) for the log-linear regression of
the terminal elimination phase was 
0.90].
DISCUSSION
The combination of novel agents with standard 5-FU/LV
has been the strategy of leading clinical research programs in
colorectal cancer. These include chemotherapeutic options such
Fig. 1 Mean (	 SD) 5-fluorouracil (5-FU) concentration-time profiles
after administration of 5-FU with and without SAM486A (SAM).
Fig. 2 Mean SAM486A concentration-time profiles after the third
administration on the five different dose levels.
Fig. 3 Mean (	 SD) SAM486A concentration-time profile of 11 pa-
tients receiving 125 mg/m2/day.
Table 6 5-Fluorouracil clearance in eight patients at the dose level
of 125 mg/m2 with and without concomitant SAM486A
Patient No.
Clearance (liter/h/m2)
Ratio
(with/without)
Without
SAM486
With
SAM486
13 37.5 32.6 0.87
14 80.0 79.5 0.99
15 73.5 75.6 1.03
16 51.7 70.6 1.37
17 69.9 80.3 1.15
18 68.2 35.3 0.52
19 75.8 47.8 0.63
21 78.9 106.4 1.35
Geometric mean 65.17 61.30 0.94
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as irinotecan and oxaliplatin and molecularly targeted agents
such as ctuximab, Iressa, and SAM486A. In this clinical study
we have demonstrated that the combination of 5-FU/LV with
SAM486A is safe and has a tolerable toxicity profile.
Novel DLTs emerge when SAM486A is combined with
5-FU when compared with the single agent data for both com-
pounds. The DLT of single-agent SAM486A was myelosup-
pression (8, 9, 22); however, DLT in the present study was
disabling fatigue. Although fatigue was reported in the single-
agent studies, it never exceeded grade 2, and it is not a feature
of the de Gramont regimen (16). Similarly, myelosuppression in
this study did not define DLT. Toxicities more pronounced than
in either single-treatment program were alopecia (30%) and
hand-foot syndrome (66%). Unchanged toxicities included par-
esthesias and flushing (probably related to the diluent for
SAM486A) and gastrointestinal toxicities (probably related to
5-FU). Cardiovascular toxicity, including arrhythmias and myo-
cardial ischemia seen with weekly SAM486A (9), was not seen
in the present study. This change in the spectrum of toxicity
suggests an interaction at the cellular but not, as we have
determined, at a PK level.
In the Phase I studies with single-agent SAM486A, the
pharmacokinetics of SAM486A were linear, indicating that the
processes of distribution and elimination were not saturated,
inhibited, nor induced. We found no PK interaction between
5-FU and SAM486A. In all of the patients, except for one, all of
the treatment cycles consisted of full-dose 5-FU/LV. It was not
possible to design this study to determine the effect of 5-FU
treatment on SAM486A pharmacokinetics using each patient as
his/her own control in a cross-over fashion. This was because of
ethical considerations concerning treatment of this patient pop-
ulation with SAM486A alone; therefore, observations about the
SAM486A pharmacokinetics are drawn from historical data. In
addition, the SAM486A dosing schedule used in this study
differed from that of single-agent studies to fit conveniently
with the de Gramont regimen. The SAM486A schedule was
shortened from 5 days of daily infusions every 3 weeks to 3 days
of daily infusions every 2 weeks. The dose intensity for
SAM486A of 187.50 mg/m2/week at the dose recommended by
this study also differed from that of the single-agent studies
[weekly 180 mg/m2/week and every four weeks doses at 100
mg/m2/week (8, 9)]. These factors make a rigorous comparison
among the three SAM486A schedules difficult; nevertheless, the
general features of the SAM486A concentration-time profile
after i.v. infusion in this study are comparable with those of the
study using the 4-week weekly treatment schedule. Mean
AUC0- and Cmax values from the 5-day schedule were 39,200
ngh/ml and 2,470 ng/ml, respectively, for the MTD 102.4-mg/
m2/day dose (22). Adjusting for the difference in dose (125
versus 102.4 mg/m2/day) and for 3 days of dosing rather than 5
days, these values become 28,700 ngh/ml and 1,810 ng/ml,
respectively. These estimates are similar to the values of 27,400
ngh/ml and 1,640 ng/ml obtained in this study. The combina-
tion treatment of 5-FU/LV using the de Gramont regimen with
SAM486A is, therefore, feasible and maintains the maximum
dose intensity of both agents.
The response data compare favorably with the data of de
Gramont using single agent 5-FU (16). This Phase I study was
not designed to determine a response rate for the combination
therapy, but the data do suggest that this question should be
evaluated in a Phase III study. The recommended dose of
SAM486A for this study will be 125 mg/m2/daily on days 1–3
every 2 weeks.
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